NOV 08, 2017 12:00 PM PST

Combined immunohistochemistry and RNA in situ hybridization to elucidate tumor molecular heterogeneity in prostate cancer

Speaker
  • Associate Scientist, Henry Ford Health System
    Biography
      Dr. Palanisamy completed his undergraduate and graduate studies at the University of Madras, India, and is currently an Associate/Senior Scientist at the Henry Ford Health System. He also holds an adjunct faculty appointment with the Michigan Center for Translational Pathology (MCTP) at the University of Michigan. His current research program is focused on the discovery of cancer biomarkers in lymphomas and solid cancers. During his post-doctoral research at the Memorial Sloan-Kettering Cancer Center, Dr. Palanisamy's work contributed to the discovery of recurrent gene fusions in follicular and diffuse large B-cell lymphomas. He was the founding Director of Research and Development at the Cancer Genetics, Inc (CGIX), where he introduced novel approaches to develop diagnostic reagents targeting chromosomal translocations in cancer. Dr. Palanisamy pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered novel "druggable" gene fusions in prostate cancer, gastric cancer, and melanoma (Palanisamy et al., Nat Med 2010). His current research aims to understand the molecular basis of tumor heterogeneity in solid cancers, with particular focus on prostate cancer, and its impact in early diagnosis, response to treatment, and clinical outcome.

    Abstract

    Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors are highly heterogeneous and there are many studies evaluating the molecular profile or ‘fingerprint’ of prostate cancer.  Conventional analysis reviews the protein expression of key markers via serum analysis and immunohistochemistry (IHC) of the biopsy.  In this presentation we will review how RNA in situ hybridization (ISH) analysis of prostate cancer can unravel the molecular heterogeneity of the tumor, identify molecular subsets and detect key fusions and mutations of the RNA.  We will also present a comparison of IHC and ISH technology and the combination of dual color IHC and dual color ISH can be used to enhance simultaneous evaluation of DNA, RNA and protein, revealing the molecular profile of prostate cancer.


    Show Resources
    You May Also Like
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    NOV 08, 2017 12:00 PM PST

    Combined immunohistochemistry and RNA in situ hybridization to elucidate tumor molecular heterogeneity in prostate cancer


    Specialty

    Research

    Health

    Life Science

    Cell Biology

    Research And Development

    Blood

    Immunology

    University

    Cancer

    Molecular Biology

    Earth Science

    Personalized Medicine

    Animal Research

    Geography

    North America40%

    Europe40%

    Asia20%

    Registration Source

    Website Visitors100%

    Job Title

    Medical Laboratory Technician100%

    Organization

    Hospital40%

    Research Institute20%

    Academic Institution20%

    Manufacturer - Other20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more